CCI
TXMD icon

Columbus Circle Investors’s TherapeuticsMD TXMD Stock Holding History

Columbus Circle Investors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,950
Closed -$702K – 293
2017
Q1 		$702K Buy
+1,950
New +$603K 0.01% 260

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Columbus Circle Investors's TXMD Position: Q4 2017 in Review

Columbus Circle Investors sold out of TherapeuticsMD (TXMD) in Q4 2017, closing a stake of 40,356 shares — an estimated $10.7M sold.

Columbus Circle Investors first reported a position in TXMD in Q1 2015 and held it in 9 quarters. The position peaked at $13.2M in Q1 2017. 144 funds tracked by Wall St. Rank hold TXMD as of Q4 2017.

  • Columbus Circle Investors reported no remaining TherapeuticsMD position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 40,356 TherapeuticsMD shares in Q4 2017, an estimated $10.7M.
  • Columbus Circle Investors first reported a position in TherapeuticsMD in Q1 2015 and held it in 9 quarters.
  • Columbus Circle Investors's TherapeuticsMD position peaked at $13.2M in Q1 2017.
  • 144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.